萬科表示理解投資者對發行價的擔心,公司融資決策也會綜合考慮市場環境、股價情況、自身發展情況以及相關方面的溝通意見,充分保障現有股東利益
格隆匯8月16日丨有投資者向萬科A(000002.SZ)提問,“請問A股增發事項進行到哪一步了?還會進行低價增發嗎?”
萬科A回覆稱,增發方案需要通過深交所審核,並獲得中國證監會作出同意註冊的決定後方可實施。公司收到交易所關於方案的問詢函後,由於問詢函涉及的部分事項需要進一步落實和完善,公司向深交所申請延期提交回復。同時,我們理解投資者對發行價格的擔心,公司的融資決策也會綜合考慮市場環境、股價情況、自身發展情況以及相關方面的溝通意見,充分保障現有股東利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.